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Abstract
Background: Parkinson’s disease (PD) is an age-related progressive neurodegenerative disorder caused by
selective loss of dopaminergic neurons from the substantia nigra (SN) to the striatum. The initial factor that triggers
neurodegeneration is unknown; however, inflammation has been demonstrated to be significantly involved in the
progression of PD. The present study was designed to investigate the role of the pro-inflammatory cytokine
interleukin-1 (IL-1) in the activation of microglia and the decline of motor function using IL-1 knockout (KO) mice.
Methods: Lipopolysaccharide (LPS) was stereotaxically injected into the SN of mice brains as a single dose or a
daily dose for 5 days (5 mg/2 ml/injection, bilaterally). Animal behavior was assessed with the rotarod test at 2 hr
and 8, 15 and 22 days after the final LPS injection.
Results: LPS treatment induced the activation of microglia, as demonstrated by production of IL-1β and tumor
necrosis factor (TNF) α as well as a change in microglial morphology. The number of cells immunoreactive for
4-hydroxynonenal (4HNE) and nitrotyrosine (NT), which are markers for oxidative insults, increased in the SN, and
impairment of motor function was observed after the subacute LPS treatment. Cell death and aggregation of
α-synuclein were observed 21 and 30 days after the final LPS injection, respectively. Behavioral deficits were
observed in wild-type and TNFα KO mice, but IL-1 KO mice behaved normally. Tyrosine hydroxylase (TH) gene
expression was attenuated by LPS treatment in wild-type and TNFα KO mice but not in IL-1 KO mice.
Conclusions: The subacute injection of LPS into the SN induces PD-like pathogenesis and symptoms in mice that
mimic the progressive changes of PD including the aggregation of α-synuclein. LPS-induced dysfunction of motor
performance was accompanied by the reduced gene expression of TH. These findings suggest that activation of
microglia by LPS causes functional changes such as dopaminergic neuron attenuation in an IL-1-dependent
manner, resulting in PD-like behavioral impairment.
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Background
Lipopolysaccharide (LPS) is a bacterial endotoxin known
to stimulate immune responses [1]. In in vivo experiments,
LPS activates the microglia, resulting in the release of in-
flammatory cytokines such as interleukin-1β (IL-1β)
and tumor necrosis factor α (TNFα), which contribute
to neurodegeneration [1-5]. Activation of the microglia
has also been observed during the development of neu-
rodegenerative conditions such as Alzheimer’s disease
(AD), Parkinson’s disease (PD) and multiple sclerosis
[6-8]. Several epidemiological studies have shown that
non-steroidal anti-inflammatory drugs are associated
with a reduced risk of developing PD [9-11]. These
phenomena suggest that inflammation is implicated in
neurodegenerative diseases [12]. PD is an age-related
progressive neurodegenerative disorder caused by the se-
lective loss of dopaminergic neurons from the substantia* Correspondence: stanaka@pharm.showa-u.ac.jp
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nigra (SN) to the striatum [13]. However, the initial fac-
tor that triggers neurodegeneration is unknown. PD
animal models have been created by exposing animals
to chemical toxins such as 1-methyl 4-phenyl 1,2,3,6,-
tetrahydropyridine (MPTP) [14-16] and 6-hydroxydopamine
(6-OHDA) [17]. These toxins selectively modulate
dopaminergic neurons via the uptake by the dopamine
transporter. However, these animal models do not en-
compass all the prevailing pathologies of PD. Therefore,
we designed a PD animal model where there is neuro-
inflammation in the mouse brain. In our previous stud-
ies, we demonstrated that subacute administration of
LPS (20 μg/2 μL/injection, daily, bilaterally for 5 con-
secutive days) into the CA1 region of the rat and mouse
hippocampus activated the microglia and increased
production of IL-1β and TNFα, concomitantly resulting
in learning and memory deficits in the animals as
assessed using a step-through passive avoidance test
[5,18]. These results suggest that inflammation affects
neuronal function. Furthermore, IL-1β plays an import-
ant role in LPS-induced impairment of learning and
memory using IL-1α/β knockout (KO) mice [18]. In the
present study, we modified the regimen and obtained
evidence that suggests there are PD-like pathological
changes and symptoms in the animal model. In
addition, LPS-induced microglial activation causes tox-
icity in dopaminergic neurons in an IL-1-dependent
manner. The results of the present study may lead to a
better understanding of the roles of IL-1 in the activa-




The following reagents were obtained from commercial
sources: LPS (from Escherichia coli serotype 055:B5;
L2880, endotoxin level 3000000 EU/mg), monoclonal anti-
mouse glial fibrillary acidic protein (GFAP) antibody from
Sigma-Aldrich (St Louis, MO), monoclonal goat anti-
mouse CD11b antibody from Serotec Ltd (Oxford, UK),
goat anti-murine IL-1β antibody from R&D Systems
(Minneapolis, MN), polyclonal rabbit anti-Iba1 anti-
body from Wako Pure Chemical Industries (Osaka,
Japan), polyclonal anti-3-nitrotyrosine antibody, Alexa
Fluor 546 donkey anti-goat IgG antibody, Alexa Fluor
488 goat anti-rat IgG antibody and Alexa Fluor 488
goat anti-mouse IgG antibody from Molecular Probes
(Eugene, OR), monoclonal anti-α-synuclein antibody
from Santa Cruz Biotechnology, Inc (Dallas, TX), poly-
clonal anti-4-hydroxynonenal (4HNE) antibody from
ENZO Life Sciences, Inc (Famingdale, NY) and anti-
nitrotyrosine (NT) antibody from Merck (Darmstadt,
Germany). All other chemicals were of analytical or the
highest grade commercially available.
Animals, surgical operations and LPS treatment
All animal experiments were conducted in accordance
with the Showa University Animal Experiment and Wel-
fare Regulations. The IL-1 KO male mice, carrying a null
mutation in both the IL-1α and IL-1β genes, and the
TNFα ΚΟ male mice were established by Horai et al.
[19] and Tagawa et al. [20], respectively. Male BALB/c
mice were purchased from Sankyo Laboratory Service
(Tokyo, Japan). The mice (at 9 to 10 weeks old) were
anesthetized with sodium pentobarbital (50 mg/kg intra-
peritoneally) and immobilized in a stereotaxic frame.
Two guide cannulas were implanted and used to inject
LPS into both sides of the substantia nigra pars reticulata
(SNR) (2.92 mm posterior, 1.25 mm lateral and 4.95 mm
ventral to the bregma). These cannulas were fixed to the
skull with dental cement. Eight days after surgery, the
mice were injected bilaterally with either LPS (5 μg) dis-
solved in 2 μL of phosphate-buffered saline (PBS) or PBS
alone under isoflurane anesthesia. Acute treatment with
PBS or LPS (5 μg/2 μL/injection, bilaterally) was carried
out to study the immunohistochemistry of the microglia.
Subacute PBS or LPS injections (5 μg/2 μL/injection, bilat-
erally) were administered daily for 5 consecutive days
under isoflurane anesthesia. These animals were used for
behavioral tests, gene expression experiments and to study
the immunohistochemistry of the brain section.
Behavioral analysis: the rotarod test
Motor coordination was assessed with a rotating rod ap-
paratus (Panlab Harvard Apparatus, Barcelona, Spain).
The rod was 3 cm in diameter. The mice were placed on
the rod when it was rotating at 4 rpm. The rotation speed
was increased from 4 to 40 rpm within 5 min. The latency
was recorded for each animal. This is the time (in sec-
onds) before they fall. Each mouse was tested three times
and the median time of the three trials was calculated.
The results are expressed as the mean ± standard error of
the mean (SEM) in each group.
Immunohistochemistry
Six hours after acute LPS or PBS treatment, the mice
were anesthetized with pentobarbital and were perfused
transcardially with saline followed by 0.1 M phosphate
buffer (PB, pH 7.2) containing 2% paraformaldehyde
[21]. The brains were removed and immersed for 1 day
in 0.1 M PB containing 2% paraformaldehyde and then
for 2 days in 0.1 M PB containing 20% sucrose. The
brains were then embedded in a mixture of 20% sucrose
in 0.1 M PB and Tissue Teck (2:1; Miles Inc, Elkhart,
IN), frozen on dry ice, and stored at −80°C until studied.
Subsequently, 10 μm sections were cut with a cryostat
and mounted onto gelatin-coated slides.
For staining of IL-1β, CD11b and tyrosine hydroxylase
(TH), sections were pre-incubated in 5% normal horse
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serum. The sections were incubated with goat anti-
mouse IL-1β antibody (1:100) and then were rinsed and
incubated with Alexa 546-labeled donkey anti-goat IgG
antibody (1:400). After that, they were incubated with
rat anti-mouse CD11b antibody (1:100) followed by la-
beling with Alexa 488-labeled goat anti-rat IgG antibody
(1:400). Then they were incubated with polyclonal anti-
TH antibody (1:1000) followed by labeling with Alexa
350-labeled goat anti-rabbit IgG antibody (1:400).
For staining of 4HNE and NT, following pre-incubation in
5% normal horse serum sections were incubated with rabbit
anti-4HNE antibody (1:500) or rabbit anti-NT antibody
(1:500) followed by labeling with Alexa 546-labeled goat
anti-rabbit IgG antibody (1:400) and then incubated with
4',6-diamidino-2-phenylindole (DAPI) solution (1:10000) to
stain the nuclei.
For staining of α-synuclein, following pre-incubation
in 5% normal goat serum, sections were incubated with
monoclonal anti-α-synuclein antibody(1:500) followed
by labeling with Alexa 546-labeled goat anti-mouse IgG
antibody (1:400). Then they were incubated with poly-
clonal anti-TH antibody (1:1000), followed by Alexa
488-labeled goat anti-rabbit IgG antibody (1:400) and
DAPI solution. Labeling was imaged with a fluorescence
microscope (Olympus AX-70; Olympus, Tokyo, Japan).
For TH immunostaining using diaminobenzidine, the
mice were sacrificed 6 hr after the final injection of the
subacute treatment. Slice was prepared as presented
above. Slice sections were pre-incubated in 5% normal
goat serum after endogenous peroxidase blocking by 0.1
M PB containing 0.3% H2O2 and incubated with poly-
clonal anti-TH antibody (1:1000). The sections were
rinsed and incubated with biotinylated horse anti-rabbit
IgG (1:1000). Then they were incubated in an avidin-
biotin complex solution followed by diaminobenzidine
(DAB kit, Vector, Burlingame, CA).
Fluoro-Jade B staining was used to detect neurodegen-
erative cells [22]. Sections were fixed with 4% parafor-
maldehyde solution for 20 min. After washing twice
with PBS and once with water, the sections were
immersed in 0.06% KMnO4 for 15 min and then rinsed
three times with purified water. Fluoro-Jade B solution
(0.01% Fluoro-Jade B: 0.1% acetic acid = 1:19) was ap-
plied for 30 min at room temperature and then rinsed
off with purified water, four times. The sections were
dried with cold air and immersed three times in xylene
for 2 min. One drop of marinol was put on top and a
cover was placed on them. Labeling was imaged with a
fluorescence microscope (Olympus AX-70; Olympus,
Tokyo, Japan).
Gene expression
The mice were decapitated 6 hr after the acute PBS or
LPS injection or 6 hr after the final PBS or LPS injection
of the subacute treatment. The midbrains were dissected
according to the method of Glowinski and Iversen [23]
and stored at −80°C until use. Total RNA was extracted
using the QIAGEN RNeasy Lipid Tissue Mini kit (QIA-
GEN, Hilden, Germany). Real-time RT-PCR was carried
out using QuantiTect SYBR Green RT-PCR system
(QIAGEN). Primers for IL-1β, TNFα, TH and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) were pre-
pared by QuantiTect Primer Assays (QIAGEN). The
amplification conditions were 40 cycles at 94°C for 15 s,
55°C for 30 s and 72°C for 30 s. Quantitative data were
obtained from the relative standard curve. mRNA ex-
pression was normalized using GAPDH as an endogen-
ous control.
Statistical analysis
Immunostaining in the substantia nigra pars compact
(SNC) was quantified by counting positively stained
cells. The number of positively stained cells in four brain
sections was counted and averaged (cells/mm2). The
statistical analysis used the Mann–Whitney test for the
immunostaining, behavioral and gene expression data.
Results
Activation of the microglia after lipopolysaccharide
treatment
An experiment was conducted to determine whether the
microglia was activated by acute LPS treatment (5 μg/
2 μL/injection). There were many TH antibody-labeled
dopaminergic neurons in the SNC. Immunohistochemical
analysis revealed no IL-1β immunoreactivity in the SNC
from mice treated with PBS (Figure 1A). In contrast, cells
with strong immunoreactivity for IL-1β were observed
6 hr after the LPS injection. To identify the cells ex-
pressing IL-1β, a triple-label immunohistochemical
study was performed for IL-1β, CD11b and TH. IL-1β
immunopositive cells were co-localized with cells immu-
noreactive to CD11b. In the early stage of activation, LPS
induced an increase in IL-1β signals in the microglia, the
shape of which remained in the ramified form 6 hr after
the acute LPS treatment. The gene expressions of IL-1β
and TNFα in the midbrain were still noticeably higher 6
hr after the acute LPS treatment (Figure 1B).
We demonstrated the long-term activation of the
microglia after the subacute treatment with LPS for 5 days
(Figure 2). In the SN of mice injected with PBS, the major-
ity of the CD11b immunopositive cells exhibited a resting
or ramified state (Figure 2A, upper rows). After the sub-
acute LPS treatment, the CD11b-immunopositive cells
were activated, as indicated by an increased number of
cells (Figure 2B) as well as a change in their morphology
to a round and blunt shape (amoeboid form, Figure 2A,
lower rows). The CD11b-immunopositive cells had an ac-
tivated phenotype. These results suggest that the subacute
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LPS treatment caused a sustained activation of the micro-
glia, resulting in an increase in the number of microglial
cells and morphological changes.
Detection of oxidative stress
4HNE is a product of lipid peroxidation and its in-
creased production is a biomarker of oxidative stress.
The number of 4HNE-positive cells in the SNC was sig-
nificantly increased 6 hr after the final LPS injection
(Figure 3A,B, upper row). NT is an indicator of cell
damage, the activation of inflammation and NO produc-
tion [39]. NT-immunopositive cells were seen to in-
crease up to fourfold 6 hr after the final LPS injection
compared with the PBS-treated group (Figure 3A,B,
lower row). These results suggest that oxidative stress
was induced in the SNC by the subacute LPS treatment.
Detection of cell death using Fluoro-Jade B and tyrosine
hydroxylase immunostaining
Cell death was seen in coronal sections of the SN using
Fluoro-Jade B staining (Figure 4A). Six hr after the final
injection, degenerating neurons stained with Fluoro-Jade
B were not observed. However, 21 and 30 days after the
final injection, Fluoro-Jade B-positive cells were detected
in a similar manner as observed in the positive control
specimens prepared after a traumatic cortical brain in-
jury. Furthermore, the number of TH antibody-labeled
dopaminergic neurons in the SNC decreased 6 hr after
the final LPS injection (Figure 4B). These results indicate
that delayed cell death was induced in the SNC by the
subacute LPS treatment.
α-synuclein expression in lipopolysaccharide-treated mice
We performed an immunohistochemical analysis to see if
there was any α-synuclein protein in the SNC (Figure 5).
α-synuclein-immunopositive cells were observed 30 days
after the final LPS injection (Figure 5A). α-synuclein gene
expression in the midbrain area was unchanged 6 hr after
the final LPS treatment compared with its expression in
the PBS-treated group (data not shown). However, 30 days
after the final LPS injection, α-synuclein gene expression
Figure 1 Expression of inflammatory cytokine in an acute LPS-treated mouse. (A) Immunohistochemical analysis of the effect of LPS
treatment on the microglia in the SNC. PBS (2 μL/injection) or LPS (5 μg/2 μL/injection) was injected into the SNR bilaterally. These representative
photomicrographs are coronal sections of the SNC at 6 hr after PBS (upper row) or acute LPS treatment (lower row). Triple immunofluorescence
staining was performed with CD11b (green), IL-1β (red) and TH (blue) antibodies. Immunoreactivity for IL-1β was co-localized with that for CD11b after
LPS treatment (yellow in the merged photomicrograph). Scale bars: 20 μm (B) Effect of LPS treatment on the gene expression of inflammatory cytokine
in the midbrain. The midbrain was obtained 6 hr after the acute LPS treatment. Values are expressed as percentages of those in the PBS-treated group
and represented as mean ± SEM. *P < 0.05 compared with the PBS-treated group. IL, interleukin; LPS, lipopolysaccharide; PBS, phosphate-buffered
saline; SEM, standard error of the mean; SNC, substantia nigra pars compact; SNR, substantia nigra pars reticulata; ΤΗ, tyrosine hydroxylase.
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was significantly increased to 170% of that for the PBS-
treated group (Figure 5B).
Assessment of animal behavior using the rotarod test
Behavioral tests were performed 2 hr and 8, 15 and 22
days after the final LPS injection. The latency of the
mice increased during the trial (Figure 6). In wild-type
mice, LPS produced a lower latency to fall off, which
was significant 15 days and 22 days after the final injec-
tion. These results suggest that the LPS treatment re-
sulted in behavioral impairment of the motor function.
We used genetically modified animals to determine
whether the pro-inflammatory cytokine was involved in
the LPS-induced behavioral deficit. The behavioral tests
were performed with the IL-1α/β double KO and TNFα
KO mice treated either with PBS or LPS. The latency of
the IL-1 KO and TNFα KO mice also increased during
the trial, like the wild-type mice (Figure 6). TNFα KO
mice treated with LPS had a significantly lower latency
to fall off 2 hr, 8 days and 22 days after the final LPS in-
jection. However, there was no difference between the
PBS and LPS treatments for the IL-1 KO mice. These re-
sults suggest that the LPS treatment caused impairment
of the motor function in the wild-type and TNFα KO
mice, but not in the IL-1 KO mice.
Tyrosine hydroxylase gene expression in wild-type, TNFα
and IL-1 KO mice
We analyzed the gene expression of TH, a marker for
dopaminergic and noradrenergic neurons, in the wild-type,
TNFα and IL-1 KO mice 6 hr after the final LPS injection.
The subacute LPS treatment significantly suppressed TH
Figure 2 Immunohistochemical analysis of the effect of the subacute LPS treatment on CD11b-positive microglia. PBS (2 μL/injection,
bilaterally) or LPS (5 μg/2 μL/injection, bilaterally) was injected into the SNR daily for 5 consecutive days. (A) Representative photomicrographs
are coronal sections of the SNC 6 hr after the final PBS (upper rows) or LPS treatment (lower rows). Double immunofluorescence staining was
performed with a CD11b antibody (green) and DAPI (blue). Scale bars: 50 μm (B) Number of CD11b immunopositive cells in the SNC. The
number of microglial cells was counted between 200 μm and 300 μm from the injection site. The results are expressed as the mean ± SEM for
four mice in each group. DAPI, 4',6-diamidino-2-phenylindole; IL, interleukin; LPS, lipopolysaccharide; PBS, phosphate-buffered saline; SEM, standard
error of the mean; SNC, substantia nigra pars compact; SNR, substantia nigra pars reticulata.
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gene expression in the wild-type and TNFα KO mice, but
not IL-1 KO mice (Figure 7). These results for TH expres-
sion are in agreement with those obtained from the behav-
ior tests.
Discussion
In the present study, we investigated whether in vivo ac-
tivation of the microglia leads to impaired neuronal
function and found that LPS-induced functional out-
comes in terms of decreased motor performance corre-
lated well with changes in immunohistochemistry and
gene expression.
PD models have been created by exposing animals to
toxins such as MPTP [14-16] and 6-OHDA [17]. These
toxins have been demonstrated to cause PD-like symp-
toms with massive losses of dopaminergic neurons in
the SN. These toxins are selectively taken up by dopa-
minergic neurons via the dopamine transporter and
cause neuronal cell death without α-synuclein aggrega-
tion. In contrast, neuronal cell death is not believed to
be the first event in the development of PD. What trig-
gers PD in humans has not been determined. Therefore,
these toxins do not induce changes that completely
mimic PD-like pathology.
We chose LPS to induce microglial activation and
neuronal inflammation in the SN of mice. In the LPS-
induced inflammation model, dopaminergic neurons
were not directly injured by the endotoxin, which may
cause deterioration of neurons via the microglia. The
present study indicated that LPS treatment caused the
activation of the microglial cells that produce IL-1β and
TNFα as well as changes in microglial morphology.
These findings are comparable to those previously re-
ported for our rat and mouse models [5,18], in which LPS
injected into the hippocampus induced learning and
memory deficits. TNFα and IL-1β are elevated in patients
with PD [24-26] and animal models [27,28]. The activated
microglia increases the secretion of pro-inflammatory cy-
tokines and activates pro-oxidant enzymes such as nico-
tinamide adenine dinucleotide phosphate oxidase and
inducible nitric oxide synthase (iNOS), resulting in the
production of reactive oxygen species (ROS) and nitric
oxide [29,30].
Oxidative stress contributes to the neurodegenerative
process in AD and PD [31,32]. PD is characterized by the
selective loss of dopaminergic neurons in the SN, and
dopamine has been suggested to be the main endogenous
toxin causing oxidative stress in the genesis of PD [33].
Figure 3 Immunohistochemical analysis of the effect of subacute LPS treatment on oxidative stress markers. PBS (2 μL/injection,
bilaterally) or LPS (5 μg/2 μL/injection, bilaterally) was injected into the SNR daily for 5 consecutive days. (A) Representative photomicrographs are
coronal sections of the SNC region 6 hr after the final PBS (upper row) or LPS treatment (lower row). Double immunofluorescence staining was
performed with 4HNE (red, upper row) or NT (red, lower row) antibody and DAPI (blue). Scale bars: 20 μm (B) Numbers of 4HNE and NT
immunopositive cells in the SNC. The results are expressed as the mean ± SEM for four mice in each group. 4HNE, 4-hydroxynonenal; DAPI,
4',6-diamidino-2-phenylindole; LPS, lipopolysaccharide; PBS, phosphate-buffered saline; SEM, standard error of the mean; SNC, substantia nigra
pars compact; SNR, substantia nigra pars reticulata.
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Dopaminergic neurons are vulnerable to oxidative stress.
Dopamine is easily oxidized by molecular oxygen to pro-
duce ROS such as superoxide anions and hydrogen perox-
ide and forms aminochrome via dopamine o-quinone
[34]. Iron accumulates in the SN of patients with PD [35].
Auto-oxidation of dopamine is stimulated by iron in pa-
tients with PD, which causes the degeneration of dopa-
minergic neurons by enhancing oxidative stress [34].
Levels of free and protein-bound 4HNE, a toxic aldehyde
produced by the peroxidation of fatty acids, were signifi-
cantly elevated in the ventricular fluid of patients with AD
[36] and a PD animal model [37]. 4HNE induces apoptosis
with caspase activation and DNA fragmentation [38]. In
our LPS-induced animal model, we detected an increase
in the number of cells immunopositive for 4HNE, which
could be involved in neuronal cell death. We also ob-
served that LPS increased the number of cells immunopo-
sitive for NT, which has been identified as an indicator of
cell damage and inflammation as a result of the produc-
tion of NO and oxidative stress [39]. LPS stimulates the
induction of iNOS and its product NO reacts with super-
oxide to produce peroxynitrite and eventually nitration of
proteins, which might contribute to disturbing protein
functions resulting in the pathological processes seen dur-
ing neurodegeneration.
α-synuclein is a major component of Lewy bodies, a
pathological hallmark of PD, and is involved in neurode-
generation [40]. It has been reported that LPS stimulates
the production of α-synuclein in the SN of rats [41]. The
present study demonstrated that there was α-synuclein
gene expression and cell death 22 and 30 days after the
final LPS injection, respectively. However, the changes in
animal behavior started just after the final LPS injection,
suggesting that impairment of the motor function ap-
pears before cell death. These results suggest that the
subacute injection of LPS into the SNR induces PD-like
pathogenesis and symptoms in mice, which mimic the
progressive changes of PD including the aggregation of
α-synuclein that causes the dysfunction of motor per-
formance. Therefore, a subacute LPS treatment could be
a novel regimen to create animal models of PD.
We did not determine the type of cells that took part
in the delayed cell death in this study. It is well known
that 80% of neurons in the SNC are dopaminergic.
Numbers of TH-immunopositive cells decreased 6 hr
after the LPS final injection. Therefore, it is suggested
that Fluoro-Jade B-stained cells are dopaminergic neu-
rons in the SNC.
Several reports attest the involvement of IL-1 in neuro-
degenerative diseases. Increased iNOS immunoreactivity,
Figure 4 Detection of cell death using Fluoro-Jade B and TH immunostaining. PBS (2 μL/injection, bilaterally) or LPS (5 μg/2 μL/injection,
bilaterally) was injected into the SNR daily for 5 consecutive days. (A) The representative photomicrographs of Fluoro-Jade B staining are coronal
sections of the SNC 6 hr, 21 days and 30 days after the final PBS (left) or LPS treatment (right). The positive control was prepared after a traumatic
brain injury (TBI) in the cortex. (B) The representative photographs of TH immunostaining using diaminobenzidine, are coronal sections of the SN
6 hr after the final PBS (left) or LPS treatment (right). LPS, lipopolysaccharide; PBS, phosphate-buffered saline; SN, substantia nigra; SNC, substantia
nigra pars compact; SNR, substantia nigra pars reticulata; ΤΗ, tyrosine hydroxylase.
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which is normally observed after brain ischemia, is dimin-
ished in IL-1 KO mice. These mice exhibit markedly re-
duced neuronal loss and apoptotic cell death when they
experience a transient cardiac arrest [42]. In a spinal cord
injury model, the size of the lesion area decreased in IL-1
KO mice compared with wild-type mice [43]. We previ-
ously demonstrated that LPS-induced deficits of learning
and memory did not occur for IL-1 KO mice [18]. These
findings indicate that IL-1 plays an important role in neu-
rodegenerative disorders in which a neuronal dysfunction
Figure 6 Effect of subacute LPS treatment on performance in the rotarod test for wild-type, IL-1 KO and TNFα KO mice. PBS
(2 μL/injection, bilaterally, open column) or LPS (5 μg/2 μL/injection, bilaterally, closed column) was injected into the SNR daily for 5 consecutive
days. The rotarod test was conducted at 2 hr and 8, 15 and 22 days after the final PBS or LPS treatment. The test was performed three times and
latency to fall off was recorded for each trial. The median latency time was calculated for each mouse. The results are expressed as the mean ±
SEM in each group. *P < 0.05 compared with the PBS-treated group. IL, interleukin; KO, knockout; LPS, lipopolysaccharide; PBS, phosphate-
buffered saline; SEM, standard error of the mean; TNF, tumor necrosis factor.
Figure 5 Immunohistochemical analysis of the effect of subacute LPS treatment on α-synuclein. PBS (2 μL/injection, bilaterally) or LPS
(5 μg/2 μL/injection, bilaterally) was injected into the SNR daily for 5 consecutive days. (A) Representative photomicrographs are coronal sections
of the SNC 30 days after the final PBS (upper) or LPS treatment (lower). Triple immunofluorescence staining was performed with α-synuclein (red)
antibody, TH (green) antibody and DAPI (blue). Scale bars: 20 μm (B) Effect of LPS treatment on the gene expression of α-synuclein in the
midbrain 30 days after the final LPS treatment. Values are expressed as percentages of those in the PBS-treated group and represented as mean ± SEM.
*P < 0.05 compared with the PBS-treated group. DAPI, 4',6-diamidino-2-phenylindole; LPS, lipopolysaccharide; PBS, phosphate-buffered saline;
SEM, standard error of the mean; SNC, substantia nigra pars compact; SNR, substantia nigra pars reticulata; ΤΗ, tyrosine hydroxylase.
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is associated with the activation of the microglia and in-
creased IL-1 expression.
The present study demonstrated that behavioral defi-
cits do not occur following a subacute LPS treatment in
IL-1 KO mice. TH gene expression, the late-limiting en-
zyme for dopamine synthesis, was attenuated by the LPS
treatment in wild-type and TNFα KO mice, but not in
IL-1 ΚΟ mice. Impairment of the motor function was
accompanied by an alteration of TH gene expression. It
appears that increased IL-1 expression in the early stage
of PD may trigger microglial activation and may be in-
volved in neurodegeneration. Thus, neuroinflammation
including an increase of IL-1 levels and augmentation of
its signaling pathway may contribute to the dopamin-
ergic dysfunction. If we had checked dopamine levels,
we may have found direct evidence for dopaminergic
neuron attenuation and motor dysfunction. We will
check dopamine levels in the following study. Our
present results suggest that IL-1 plays an important role
in mediating LPS-induced functional changes of motor
performance. However, the precise mechanism by which
microglial activation occurs remains to be determined.
Conclusions
The findings presented in this study provide evidence
that activation of the microglia by LPS causes functional
changes such as dopaminergic neuron attenuation in an
IL-1-dependent manner, resulting in PD-like behavioral
impairment. The LPS-induced animal model for PD
could be a useful tool for clarifying mechanisms
underlying the neurodegenerative disease and, therefore,
should be evaluated further.
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